The findings underscore the central role of TLR4 signaling in the pathogenesis of del(5q) MDS and AML, demonstrating how aberrant innate immune responses driven by TIFAB deletion and TRAF6 stabilization promote disease progression. This evidence concerns the gene TRAF6 and acute myeloid leukemia.